









Markets
/
Stocks
/
nasdaq-scph
/

scPharmaceuticals Inc

SCPH

5.670USD

0.000

Close 11/07, 16:00（ET）Quotes delayed by 15 min

302.16MMarket Cap

LossP/E TTM



scPharmaceuticals Inc

5.670

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of scPharmaceuticals Inc

Currency: USD Updated: 2025-10-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals.

scPharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

99 / 174

Overall Ranking

263 / 4702

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

12.088

Target Price

+113.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

scPharmaceuticals Inc Highlights

StrengthsRisks

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.33M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 131.14.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 43.14M shares, decreasing 13.57% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.84M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 3.31.

Financial Health

Currency: USD Updated: 2025-10-07

Its latest quarterly revenue reached 16.04M, representing a year-over-year increase of 99.17%, while its net profit experienced a year-over-year increase of 5.47%.

Score

Industry at a Glance

Previous score

6.52

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

scPharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-07

The company’s current valuation score is 5.76, which is lower than the Pharmaceuticals industry's average of 7.18. Its current P/E ratio is 0.00, which is NaN% below the recent high of 0.00 and +Inf% above the recent low of -8.94.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/174

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-07

The company’s current earnings forecast score is 6.50, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for scPharmaceuticals Inc is 9.00, with a high of 25.00 and a low of 5.35.

Score

Industry at a Glance

Previous score

6.50

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-07

The company’s current price momentum score is 6.45, which is lower than the Pharmaceuticals industry's average of 7.10.

Score

Industry at a Glance

Previous score

4.33

Change

2.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.768

Neutral

RSI(14)

4.784

Oversold

STOCH(KDJ)(9,3,3)

33.288

Sell

ATR(14)

0.437

High Vlolatility

CCI(14)

-466.667

Oversold

Williams %R

100.000

Oversold

TRIX(12,20)

-0.138

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.532

Buy

MA10

5.089

Buy

MA20

5.357

Buy

MA50

5.236

Buy

MA100

4.676

Buy

MA200

3.844

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-07

The latest institutional shareholding proportion is 67.81%, representing a quarter-over-quarter decrease of 18.36%. The largest institutional shareholder is The Vanguard, holding a total of 1.84M shares, representing 3.42% of shares outstanding, with 18.75% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

6.06M

Rubric Capital Management LP

4.60M

-3.62%

Lytton (Laurence W)

2.94M

+61.35%

Lundbeckfond Invest

2.86M

Glazer Capital, LLC

2.47M

The Vanguard Group, Inc.

Star Investors

1.84M

-7.88%

Luther King Capital Management Corp.

3.54M

+13.46%

BlackRock Institutional Trust Company, N.A.

1.99M

-7.65%

Morgan Stanley & Co. LLC

1.66M

+0.80%

5AM Ventures

1.20M

Risk Assessment

Currency: USD Updated: 2025-10-07

The company’s current risk assessment score is 3.75, which is lower than the Pharmaceuticals industry's average of 5.10. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.